Role of estrogen and estrogen receptors in cancer pathology

Vesna Mandusic, Djordje Radak, Milan Markicevic, Milan Perovic, Milan Obradovic, Dimitri P. Mikhailidis, Esma R. Isenovic

1 Laboratory for radiobiology and molecular genetics, Institute Vinca, University of Belgrade, Serbia; 2 Department of Vascular Surgery, Dedinje Cardiovascular Institute, Belgrade University School of Medicine, Belgrade, Serbia; 3 Institute for Oncology and Radiology of Serbia, Belgrade, Serbia; 4 Clinical Hospital Center Zemun, Department of Gynecology, Zemun, Serbia; 5 Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free campus, University College London Medical School, University College London (UCL), London, UK

Abstract

Estrogen regulates many different and sometimes quite opposite processes in cells. Since the discovery of estrogen receptor (ER), the last few decades have resulted in a better understanding of estrogen biology. Estrogen is involved in processes leading to different pathologies in estrogen responsive tissues, not only carcinogenesis, but this was one of the most investigated fields in estrogen-related pathology. The exact role of estrogen in these pathologies is not completely understood due to the complex interplay of its receptors with other signaling pathways. This review considers the latest literature focused on estrogen and ERs as potential therapeutic targets in the treatment of malignant disease (e.g. breast, prostate, ovarian and endometrial cancer).

Introduction

Hormones regulate basic biological processes of mediating signals into the cells. There are two major types of hormones: peptide and steroid and their receptors are located in cell membrane and/or cytoplasm. Upon binding to their receptors, hormones activate different signaling pathways in cells regulating the processes of cell division, differentiation and apoptosis. Moreover, endogenous and exogenous hormones, and hormone-like substances are involved in the etiology of cancer, neurodegenerative diseases and many other pathologies. In carcinogenesis, hormones are involved in initiation but also in the progression of disease. However, due to an apoptotic effect, some hormones might have the opposite effect; for example reduce cancer risk or slow down tumor progression. On the other hand, a preserved functional hormonal pathway represents a target for anti-hormonal therapy in endocrine-related malignancies, such as breast, endometrial, ovary, prostate or testis cancers. Hormone-related carcinogenesis is of very complex etiology due to the combination of genetic susceptibility, epigenetic changes and exposure to endogenous and exogenous hormones and hormone-like substances.

Estrogen is the hormone involved in etiology of carcinogenesis in responsive tissues, such as the endometrium, breast, ovary and prostate, which are the models for studying hormonal carcinogenesis. The main effects of estrogen is usually mediated through its receptors, thereby their expression patterns (in addition to hormonal exposure and exposure to other risk factors) are one of the major determinants of incidence and progression of disease. Expression profiling in cancer is still an open issue, despite the intensive efforts in microarray-based studies.

In this review, we present some aspect of this complexity related to estrogen and its receptors as potential therapeutic targets.

Estrogen function

Since the discovery of estrogen receptor (ER) in the 1950’s, it was realized that estrogen is much more than a sex hormone. It regulates many different and sometime quite opposite processes in cells such as: growth and differentiation. Estrogen is involved in morphogenesis of the mammary gland, prostate and lungs; it is a trophic factor for neurons, and it is involved in maintaining the normal structure of mammary epithelium and fertility in females.

ERs belong to the large family of nuclear receptors. These are the family of structurally related ligand-inducible transcription factors including steroid receptors (SRs), vitamin D receptors (VDR, LXR, PPARs), thyroid/retinoid receptors (TR, RARs and RXRs) and orphan receptors. All nuclear receptors share similar structure and are activated by small lipophilic molecules: glucocorticoids, progesterone, estrogens, retinoids and fatty acid derivatives.

Mechanisms of estrogen action

There are several ways how estrogen and ER acts on cells. The main and one of the first recognized is the interaction of estrogen with ER into estrogen-ER complex, may act directly on estrogen response elements (ERE) in the promoters of estrogen responsive genes or may act by interacting with AP-1 or SP-1 complexes. This ligand-dependant activation of transcription via direct genomic action through ERE or tethering to other proteins is influenced by ligand, ER subtype and expression of different cell specific coregulators. Another mechanism, so called rapid nongenomic mechanism is not well investigated, but it is associated either with membrane ER-α or with some other membrane or cytoplasmic protein. The ligand-dependant pathways of estrogen action are shown in Figure 1. The ligand-independent mechanism of ER activation involves growth factor signaling and kinases that phosphorylate ER and thereby activate it in the absence of a ligand.

There are two receptors for estrogen, ERα (estrogen receptor alpha) and ERβ (estrogen receptor beta), and both receptors are widely expressed in tissue; the main receptor in breast and uterus (as primary target tissues for estrogen) is ERα, while ERβ seems to be the main receptor in peripheral tissues (bladder, lung, intestines and glands). Although structurally highly homologous, ERα and ERβ may have opposite functions on some promoters. Therefore, their ratio might determine transcription from downstream target genes, in cells where both are expressed. It has been

Correspondence: Esma Isenovic, Institute Vinca, University of Belgrade, Laboratory for Radiobiology and Molecular Genetics, P.O.Box 522 11000 Belgrade, Serbia. Tel./Fax. +38111.8066868 E-mail: isenovic@yahoo.com.

Key words: estrogen, breast cancer, prostate cancer, ovarian cancer, endometrial cancer.

Acknowledgements: this work was supported by grants No.173033 (to Dr E. R. Isenovic), No.41102 (to Dr D. Radak), No.173049 (Dr V. Mandusic) and No.175068 (M.Sc. M. Markicevic) from the Ministry of Science, Republic of Serbia.

Contributions: all the authors read and approved the manuscript, and believe that it is an original article, which carries new literature findings that are important to their field and encourage more research in this area.

Conflict of interest: the authors report no conflicts of interest.

Received for publication: 29 March 2011. Accepted for publication: 19 April 2011.

This work is licensed under a Creative Commons Attribution 3.0 License (by-nc 3.0).
It is well known that 50-80% of breast carcinoma patients have tumors with measurable ERα levels, i.e. ERα+ tumors;5 ERα+ tumors are sensitive to endocrine therapy.52 More than half of ERα+ breast carcinomas express progesterone receptor (PR) that mediates progesterone’s effects in the development of the mammary gland and breast carcinoma, where estrogen signaling via ERα is necessary to induce PR expression.25 The status of ER/PR (or steroid receptors), for primary breast cancer patients is accepted to provide potentially relevant information regarding natural or clinical course of disease.56 While steroid receptor status of the primary breast cancer is a prognostic indicator for patient’s outcome, though it is considered a weak one,26 it has been proven to be a predictor of response to endocrine therapy since up to 80% of patients bearing ER+PR+ tumors respond to endocrine treatment.58

The facts that steroid status is not a powerful prognostic marker, that some breast cancer patients with steroid receptors-negative status respond to endocrine therapy and that certain number of breast carcinomas will recur after such treatment in spite of steroid receptors-positivity emphasize the need for identifying markers complementary to SR status in order to improve the prognosis and prediction of breast cancer patients. Attention has been directed to estrogen-regulated proteins, including pS2, cathepsin D and ERβ, assuming that these proteins may be indicators of a functional signal transduction pathway through which tumor cells respond to estrogen (or anti-estrogen) stimulation. In addition, the new markers related to cell cycle regulation and those detectable in circulating DNA are under intensive investigation.5

Role of estrogen in cancer pathology

There are two possible ways how estrogen initiates and promotes carcinogenesis; i) via its proliferative effects which increase the numbers of cell divisions and accumulation of mutations in DNA; ii) via estrogen metabolism accumulation of intermediary products with genotoxic effect in cells.50,51

Breast cancer

It is well known that 50-80% of breast carcinoma patients have tumors with measurable ERα levels, i.e. ERα+ tumors;5 ERα+ tumors are sensitive to endocrine therapy.52 More than half of ERα+ breast carcinomas express progesterone receptor (PR) that mediates progesterone’s effects in the development of the mammary gland and breast carcinoma, where estrogen signaling via ERα is necessary to induce PR expression.25 The status of ER/PR (or steroid receptors), for primary breast cancer patients is accepted to provide potentially relevant information regarding natural or clinical course of disease.56 While steroid receptor status of the primary breast cancer is a prognostic indicator for patient’s outcome, though it is considered a weak one,26 it has been proven to be a predictor of response to endocrine therapy since up to 80% of patients bearing ER+PR+ tumors respond to endocrine treatment.58

The facts that steroid status is not a powerful prognostic marker, that some breast cancer patients with steroid receptors-negative status respond to endocrine therapy and that certain number of breast carcinomas will recur after such treatment in spite of steroid receptors-positivity emphasize the need for identifying markers complementary to SR status in order to improve the prognosis and prediction of breast cancer patients. Attention has been directed to estrogen-regulated proteins, including pS2, cathepsin D and ERβ, assuming that these proteins may be indicators of a functional signal transduction pathway through which tumor cells respond to estrogen (or anti-estrogen) stimulation. In addition, the new markers related to cell cycle regulation and those detectable in circulating DNA are under intensive investigation.5
From a tumor biology point of view, considering possible clinical application, it is important to determine the cut-off value for defining estrogen- vs non-estrogen-regulated expression of a protein in breast cancer. Regarding pS2 or cathepsin D, discrimination of estrogen-regulated from non-estrogen-regulated protein expression in breast cancer, based on the cut-off value having not only statistical but also biological relevance, might be helpful in order to identify patients with low or high risk for developing metastases (our unpublished data) during early follow-up.

The role of ERβ and its predictive value in breast cancer is still not clear, but there is evidence that ERβ transcription is down regulated during breast tumorigenesis. It has been shown that the expression of ERα increases during the process of carcinogenesis, but the expression of ERβ seems to decrease. ERβ is under intensive investigation and its role in breast cancer appears to be of additional predictive value.

Selective estrogen receptor modulators (SERMs) are used in clinical management of ERα positive breast cancer. However, about 30% of breast cancers are initially ER negative and resistant to endocrine therapies. In addition, some initially ER positive breast cancers evolve to an estrogen-independent growth phenotype.

Moreover, it has become clear that ERs and PR in living cells represent a pool of different variant proteins; therefore, it is reasonable to propose that ER/PR status should now include ERα, ERβ and PR receptors together with some of their isoforms and functionally active splice variants. The several isoforms of ERs described at protein level and the presence of numerous mRNA splice variants suggest the possibility that expression profile of these variant proteins tumors might be involved in tumor progression and tamoxifen resistance.

Prostate cancer
In addition to androgens, estrogens also play an important role in the development of the male reproductive system. Clinical studies show that increased estrogen serum level or increased estrogen/androgen ratio are associated with increased risk of prostate cancer. ERβ was initially cloned from prostate tissue.66 ERβ was initially cloned from prostate tissue.66 Interestingly, ERβ shows that increased estrogen serum level or increased ERβ expression,71 and that ERβ correlates with poor prognosis in this disease. The biological significance of this correlation is not clear since ERβ has low affinity to estradiol but inhibits ERα-mediated estrogen signalization. A study in laser capture microdissected prostate cancer specimens also confirmed the increase ERβ mRNA expression compared with normal controls, but without detection of which isoform contributes to this finding.72 The authors also found non-significant trend to decreased ERα expression in prostate cancer tissue.

Because of the controversial findings of immunohistochemical and RNA-based studies, the exact role of ERα and ERβ, as well as androgen receptors in prostate carcinogenesis is not yet defined.

Ovarian cancer
The majority of ovarian cancers arise from the ovarian surface epithelium and only 5% from the granulosa cells. About 70% of all ovarian cancers are ER-positive, but tamoxifen does not have therapeutic potential as in breast cancer.73 Regarding the ERs subtype, ERα is expressed in tumors of epithelial and stromal origin, whereas ERβ is expressed in granulosa cell tumors point144-146. With analogy to other hormone responsive tissues, the role estrogen can be expected in etiology of ovarian tumors (at least those that arise from epithelial cells). Moreover, in the etiology of ovarian carcinogenesis gonadotropin stimulation is included, increasing the endogenous estrogen levels produced by the granulosa cells during the reproductive age.77 To date, the role of estrogen and ERs in ovarian cancer is not elucidated; this is an issue that may be partially related to the expression of different ER isoforms in ovarian carcinomas.74,75 However, in recent years the results of studies in women on long-term hormone replacement therapy showed an increased ovarian cancer incidence (together with increased mortality and other diseases related to hormonal treatment).80,81

In general, prostogens and ERβ seems to play a protective role against development of ovarian cancer, like in breast and prostate carcinomas. Decreases in ERβ expression or increased ERα/ERβ ratio in ovarian cancer is reported.70,73

Endometrial cancer
Although ERβ are expressed in most cell types in the uterus, the ERα is the main mediator of estrogen action in this organ. The vast majority of sporadic endometrial carcinomas are classified as type I carcinomas and are estrogen-related. These estrogen-related endometrial carcinomas are associated with long-term exposure to estrogen in the absence of sufficient levels of progesterone. Tamoxifen, routinely used as adjuvant treatment in breast cancer and in breast cancer prevention trials in perimenopausal women, increases the risk for endometrial cancer. This is a consequence of the agonist effect of tamoxifen on ERs in the uterus. The fact that ERβ is also expressed in the uterus suggests its potential role in pathogenesis of this disease. However, its role in endometrial carcinogenesis is rather unclear, partially due to the controversial reports of estrogen induced-ERβ transcriptional activity uterine cell lines. To date, the main efforts should be directed towards the investigation of the newer selective estrogen receptor modulators in the terms of their endometrial safety.

Conclusions
Estrogen plays an important role in development and normal function of tissues during the prenatal development, puberty and in adult age, especially during the fertile period. Consequently, estrogen is involved in processes leading to different pathologies in estrogen responsive tissues, not only in carcinogenesis, but this was one of the most investigated fields in estrogen-related pathologies to date. The exact role of estrogen in these pathologies still is not well understood due to the complex interplay of its receptors with other signaling pathways. On the other hand, today is clear that ERs actually represent a pool of a number of isoforms and splice variants; the expression profile of these variant proteins with different biological properties (e.g. ligand, DNA and co-factor binding) is probably cell-, tissue- and disease-specific. Moreover, most variants might have a predictive value and may represent new potential therapeutic targets.

References
7. Kim C, Paik S. Gene-expression-based pro-


